Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

477
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
477
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

142
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
142
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

285
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
285
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

611
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
611

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Circulating levels of leptin in different phases of the menstrual cycle - A systematic review and meta-analysis.

Journal of family medicine and primary care·2026
Same author

Socioeconomic Outcomes of Childhood Cancer Survivors in India: A Cross-Sectional Study From a Tertiary Care Childhood Cancer Survivorship Program.

JCO global oncology·2026
Same author

Continuous Positive Airway Pressure Versus Mandibular Advancement Devices Impact on Cardio-Metabolic Outcomes in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Journal of sleep research·2026
Same author

Prostate cancer and diabetes: A retrospective analysis of mortality trends in the United States (1999-2024).

Medicine·2026
Same author

Anticoagulation alone vs anticoagulation plus antiplatelet therapy in atrial fibrillation with stable coronary disease: A meta-analysis of randomized trials.

Heart rhythm O2·2026
Same author

Genotype-Phenotype Discordance in Cardiomyopathies: Pathophysiology, Clinical Expression, and Therapeutic Considerations.

Health science reports·2026

相关实验视频

Updated: Jun 9, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.1K

PCSK9抑制剂:不断变化的未来

Bijay Mukesh Jeswani1, Shubhangi Sharma2, Sawai Singh Rathore3

  • 1Department of Medicine GCS Medical College, Hospital & Research Centre Ahmedabad India.

Health science reports
|October 31, 2024
PubMed
概括

PCSK9抑制剂显著降低LDL胆固醇,降低高风险患者心血管事件的风险. 这些新型疗法为无法耐受他类药物或患有家族性高胆固醇血症的人提供了有效的替代方案.

关键词:
在PCSK9抑制剂的LDL中,PCSK9抑制剂的LDL中.胆固醇胆固醇心血管疾病心血管疾病家庭性高胆固醇血症是什么蛋白转化酶的作用亚提利辛/凯类型9

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

相关实验视频

Last Updated: Jun 9, 2025

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.1K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

科学领域:

  • 心血管医学 心血管医学
  • 药理学 药理学是指药理学的学科.
  • 脂质代谢 脂质代谢是什么

背景情况:

  • 蛋白转化酶亚素/素9型 (PCSK9) 抑制剂代表了管理高胆固醇血症的新型治疗类.
  • 这些药物增强了LDL受体的活性,从而增加了低密度脂蛋白胆固醇 (LDL-C) 从循环中的清除.
  • PCSK9抑制剂被用作类他类药物治疗的辅助药物或作为高心血管风险患者的单一疗法.

研究的目的:

  • 提出PCSK9抑制剂的最新审查,重点关注其临床有效性,安全性概况和整体意义.
  • 评估最近的临床试验对PCSK9抑制的理解和应用的影响.

主要方法:

  • 对主要心血管结局试验的审查,包括FOURIER,SPIRE-1,SPIRE-2和ODYSSEY结局.
  • 检查PCSK9在胆固醇平衡中的作用.
  • 评估新兴的治疗策略,如小干扰RNA (siRNA) 疗法,以及它们对LDL-C和脂蛋白水平的影响.

主要成果:

  • 在临床试验中,PCSK9抑制剂显示LDL-C水平降低了60%.
  • 埃沃洛库马布 (FOURIER) 和阿利罗库马布 (ODYSSEY结果) 显著降低了LDL-C和主要的不良心血管事件.
  • 像Inclisiran这样的新兴疗法在不频繁的剂量中提供持续的LDL-C降低,PCSK9抑制剂通常耐受良好,注射部位反应是最常见的副作用.

结论:

  • PCSK9抑制剂在降低LDL-C和降低心血管风险方面非常有效,为高风险个人提供了重要的治疗选择,包括那些患有家族性高胆固醇血症或他类药物不耐受的人.
  • 未来的研究方向包括优化PCSK9抑制剂疗法,探索组合治疗,并研究基因编辑技术以改善患者的治疗结果.